Your browser doesn't support javascript.
loading
Activin/Follistatin-axis deregulation is independently associated with COVID-19 in-hospital mortality
Evgenia Synolaki; Vasileios Papadopoulos; Georgios Divolis; Olga Tsachouridou; Efstratios Gavriilidis; Georgia Loli; Arriana Gavriil; Christina Tsigalou; Nikolaos R Tziolos; Eleni Sertaridou; Bhanu Kalra; Ajay Kumar; Petros Rafailidis; Arja Pasternack; Dimitrios Boumpas; Georgios Germanidis; Olli Ritvos; Symeon Metalidis; Panagiotis Skendros; Paschalis Sideras.
Afiliación
  • Evgenia Synolaki; Biomedical Research Foundation Academy of Athens, Athens, Greece
  • Vasileios Papadopoulos; First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
  • Georgios Divolis; Biomedical Research Foundation Academy of Athens, Athens, Greece
  • Olga Tsachouridou; First Department of Internal Medicine , AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Efstratios Gavriilidis; First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
  • Georgia Loli; First Department of Internal Medicine , AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Arriana Gavriil; Biomedical Research Foundation Academy of Athens, Athens, Greece
  • Christina Tsigalou; Laboratory of Microbiology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
  • Nikolaos R Tziolos; 5Fourth Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
  • Eleni Sertaridou; Intensive Care Unit, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
  • Bhanu Kalra; AnshLabs, Webster, Texas, USA
  • Ajay Kumar; AnshLabs, Webster, Texas, USA
  • Petros Rafailidis; Second Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
  • Arja Pasternack; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
  • Dimitrios Boumpas; 4th Department of Medicine, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece
  • Georgios Germanidis; First Department of Internal Medicine , AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Olli Ritvos; Department of Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
  • Symeon Metalidis; First Department of Internal Medicine , AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Panagiotis Skendros; First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
  • Paschalis Sideras; Biomedical Research Foundation Academy of Athens, Athens, Greece
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-20184655
ABSTRACT
RationaleActivins are inflammatory and tissue-repair-related members of the TGF{beta}-superfamily that have been implicated in the pathogenesis of several immuno-inflammatory disorders including sepsis/acute respiratory distress syndrome (ARDS). We hypothesized that they might be of particular relevance to COVID-19 pathophysiology. ObjectivesTo assess the involvement of the Activin-Follistatin-axis in COVID-19 pathophysiology. MethodsLevels of Activins -A, -B and their physiological inhibitor Follistatin, were retrospectively analyzed in 314 serum samples from 117 COVID-19 patients derived from two independent centers and compared with common demographic, clinical and laboratory parameters. Optimal-scaling with ridge-regression was used to screen variables and establish a prediction model. Main ResultsThe Activin/Follistatin-axis was significantly deregulated during the course of COVID-19 and was independently associated with severity and in-hospital mortality. FACT-CLINYCoD, a novel disease scoring system, adding one point for each of Follistatin >6235 pg/ml, Activin-A >591 pg/ml, Activin-B >249 pg/ml, CRP >10.3 mg/dL, LDH >427 U/L, Intensive Care Unit (ICU) admission, Neutrophil/Lymphocyte-Ratio >5.6, Years of Age >61, Comorbidities >1 and D-dimers >1097 ng/ml, efficiently predicted and monitored fatal outcome independently of multiplicity and timing of sampling (AUC 0.951{+/-}0.032, p<10-6). Validation in 35 samples derived from a third hospital indicated comparable AUC (0.958{+/-}0.086, p=0.032). ConclusionThis study unravels the link between Activin/Folistatin-axis and COVID-19 mortality and introduces FACT-CLINYCoD, a novel pathophysiology-based tool that copes with the dynamic and heterogeneous nature of COCVID-19, predicts disease outcome and supports clinical decision making. Prospective large-scale validation of this calculator, as well as investigation of the mechanisms linking Activin/Folistatin-axis to COVID-19 pathogenesis is warranted.
Licencia
cc_by_nc_nd
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint